We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
新型ADC药物靶向DLL3和B7-H3，克服SCLC耐药性。分析疗效、毒性和治疗前景。了解更多。
欧洲委员会授予Zepzelca联合atezolizumab治疗肺癌的孤儿药地位。了解EMA改革如何改变SCLC的规则以及谁从这一决定中受益。详细分析。
